Key result
High HDL-C fails as a reliable atheroprotective marker to offset established ASCVD risks.
HDL-C is not a reliable marker of atheroprotection, highlighting the need for future research to focus on functional HDL metrics rather than simply raising HDL-C levels.
HDL biology remains highly relevant, but HDL-C alone should not be interpreted as a reliable marker of atheroprotection or as a therapeutic target. Very high HDL-C should not be used to downplay established causal risk factors. Future research should prioritize functional HDL metrics, deeper phenotyping, and mechanism-aligned trials to determine whether improving HDL quality, rather than simply raising HDL-C, can reduce ASCVD risk.
No takes yet. Share an insight, caveat, or question.
Parini et al. (2026) conducted a review in ASCVD. HDL-C was evaluated. High HDL-C alone should not be interpreted as a reliable marker of atheroprotection or used to downplay established causal risk factors for ASCVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: